Adverum Biotechnologies, Inc. (NASDAQ:ADVM) headquartered in Menlo Park, will host a conference call for the investment community to discuss the 2Q20 financial results on 10th August 2020 at 4:30 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.adverum.com
Earnings Expectation
Adverum Biotechnologies, Inc. is set to announce second quarter earning results on Monday 10th August 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, ADVM to report 2Q20 loss of $ 0.28 per share from revenue of $ 0.09 million. For the full year, analysts anticipate top line of $ 0.30 million, while looking forward to loss of $ 1.18 per share bottom line.
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema.
